Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Part B Payment Model Indexing Commercial Discounts Proposed By Genentech

Executive Summary

Approach offered as alternative to more disruptive changes to Part B's existing buy-and-bill system; more aggressive proposals include new iteration of  competitive acquisition program and moving Part B drug coverage to Part D.


Related Content

Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin
Drug Pricing Reform In Medicare And Medicaid: Upcoming Regulatory Actions
Medicare Value-Based Contracting, Vendor Price Negotiation To Be Tested In Part B Demo
Shifting Medicare Part B Drugs To Part D: Legislative Prospects Cloudy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts